Skip to search formSkip to main contentSkip to account menu

0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]

Known as: FILGRASTIM 480 ug in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [NEUPOGEN], Neupogen 480 MCG per 0.8 ML Prefilled Syringe, 0.8 ML Neupogen 0.6 MG/ML Prefilled Syringe 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
RATIONALE & OBJECTIVES: Biosimilar filgrastim may offer significant cost advantages over originator filgrastim and pegfilgrastim… 
2016
2016
Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic… 
2016
2016
PurposeAnthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in… 
Highly Cited
2011
Highly Cited
2011
IntroductionMobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by… 
2001
2001
ZusammenfassungDer diabetische Fuß entsteht durch das Zusammenwirken mehrerer pathogenetischer Faktoren: Periphere Neuropathie… 
1997
1997
ZusammenfassungHintergrundG-CSF (granulocyte-colony-stimulating-factor) beschleunigt die Teilung, Reifung und Freisetzung von…